Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study

Carlos Souto Maior Borba, Maria Amelia; de Mendonça Batista, Paula; Falcão Almeida, Milena; do Carmo Rego, Maria Aparecida; Brandão Serra, Fernando; Barbour Oliveira, Julio Cesar; Nakajima, Karina; Silva Julian, Guilherme; Amorim, Gilberto

doi:10.1038/s41598-023-43131-9

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albeit standardization of TIL evaluation is still debated, distinct researchers observed better overall survival (OS) among patients with elevated lymphocytic infiltration. Moreover, higher TIL proportions in breast tumors have predicted a better response to anthracycline/taxane-based chemotherapies in both neoadjuvant and adjuvant therapy settings 4 – 6 , therapeutic regimens that are frequently implemented in Brazil for the treatment of breast cancer patients 7 .…”

Section: Introductionmentioning

confidence: 99%

Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development

Gonçalves,

Pinheiro-Rosa,

Torres

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Despite presenting a worse prognosis and being associated with highly aggressive tumors, triple-negative breast cancer (TNBC) is characterized by the higher frequency of tumor-infiltrating lymphocytes, which have been implicated in better overall survival and response to therapy. Though recent studies have reported the capacity of B lymphocytes to recognize overly-expressed normal proteins, and tumor-associated antigens, how tumor development potentially modifies B cell response is yet to be elucidated. Our findings reveal distinct effects of 4T1 and E0771 murine tumor development on B cells in secondary lymphoid organs. Notably, we observe a significant expansion of total B cells and plasma cells in the tumor-draining lymph nodes (tDLNs) as early as 7 days after tumor challenge in both murine models, whereas changes in the spleen are less pronounced. Surprisingly, within the tumor microenvironment (TME) of both models, we detect distinct B cell subpopulations, but tumor development does not appear to cause major alterations in their frequency over time. Furthermore, our investigation into B cell regulatory phenotypes highlights that the B10 Breg phenotype remains unaffected in the evaluated tissues. Most importantly, we identified an increase in CD19 + LAG-3 + cells in tDLNs of both murine models. Interestingly, although CD19 + LAG-3 + cells represent a minor subset of total B cells (< 3%) in all evaluated tissues, most of these cells exhibit elevated expression of IgD, suggesting that LAG-3 may serve as an activation marker for B cells. Corroborating with these findings, we detected distinct cell cycle and proliferation genes alongside LAG-3 analyzing scRNA-Seq data from a cohort of TNBC patients. More importantly, our study suggests that the presence of LAG-3 B cells in breast tumors could be associated with a good prognosis, as patients with higher levels of LAG-3 B cell transcripts had a longer progression-free interval (PFI). This novel insight could pave the way for targeted therapies that harness the unique properties of LAG-3 + B cells, potentially offering new avenues for improving patient outcomes in TNBC. Further research is warranted to unravel the mechanistic pathways of these cells and to validate their prognostic value in larger, diverse patient cohorts.

show abstract

Section: Introductionmentioning

confidence: 99%